11.08.2023
Outcomes of patients with cancer undergoing percutaneous left atrial appendage occlusion
verfasst von:
Siddharth Agarwal, Avirup Guha, Muhammad Bilal Munir, Christopher V. DeSimone, Abhishek Deshmukh, Zain Ul Abideen Asad
Erschienen in:
Journal of Interventional Cardiac Electrophysiology
|
Ausgabe 8/2023
Einloggen, um Zugang zu erhalten
Excerpt
Cancer is independently associated with an increased risk of atrial fibrillation (AF), especially in patients older than 65 years of age and/or in those with pre-existing cardiovascular disease [
1]. Patients with active cancer are at a higher risk of arterial and venous thrombosis and thus at a higher risk of developing ischemic stroke [
1]. Systemic anticoagulation with either low molecular weight heparin or direct-acting oral anticoagulants is complicated in patients with cancer due to thrombocytopenia, high-bleeding risk, and drug-drug interactions with chemotherapeutic agents [
1]. Recent trials have demonstrated the important role of percutaneous left atrial appendage occlusion (LAAO) in mitigating stroke risk in patients with nonvalvular AF; however, there is limited data on the safety and efficacy of LAAO device implantation in patients with cancer [
2]. Therefore, we examined the outcomes of patients with cancer undergoing LAAO device implantation in a nationally representative cohort of patients. …
